Review article: Chemokines as orchestrators of autoimmune hepatitis and potential therapeutic targets

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 3, 2014, Pages 261-279

  Czaja, A J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCL17; CHEMOKINE RECEPTOR CCL2; CHEMOKINE RECEPTOR CCL20; CHEMOKINE RECEPTOR CCL22; CHEMOKINE RECEPTOR CCL26; CHEMOKINE RECEPTOR CCL3; CHEMOKINE RECEPTOR CCL5; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CX3CL1; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCL10; CHEMOKINE RECEPTOR CXCL11; CHEMOKINE RECEPTOR CXCL16; CHEMOKINE RECEPTOR CXCL4; CHEMOKINE RECEPTOR CXCL9; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR6; UNCLASSIFIED DRUG;

APOPTOSIS; AUTOIMMUNE HEPATITIS; CELL EXPANSION; CELL MIGRATION; DISEASE ASSOCIATION; EFFECTOR CELL; HUMAN; LIVER FIBROSIS; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; TH2 CELL;

ANIMALS; CHEMOKINES; HEPATITIS, AUTOIMMUNE; HUMANS; RECEPTORS, CHEMOKINE; T-LYMPHOCYTES;

EID: 84904055092     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12825     Document Type: Review

References (215)

1. Alvarez F, Berg PA, Bianchi FB, et al,. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.
2. Manns MP, Czaja AJ, Gorham JD, et al,. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-213.
3. Gleeson D, Heneghan MA,. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut 2011; 60: 1611-29.
4. Baggenstoss AH, Soloway RD, Summerskill WH, et al,. Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution. Hum Pathol 1972; 3: 183-98.
5. Schalm SW, Korman MG, Summerskill WH, et al,. Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. Am J Dig Dis 1977; 22: 973-80.
6. Carpenter HA, Czaja AJ,. The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. Clin Liver Dis 2002; 6: 685-705.
7. Kerr JF, Cooksley WG, Searle J, et al,. The nature of piecemeal necrosis in chronic active hepatitis. Lancet 1979; 2: 827-8.
8. Fox CK, Furtwaengler A, Nepomuceno RR, et al,. Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis. Liver 2001; 21: 272-9.
9. Bai J, Odin JA,. Apoptosis and the liver: relation to autoimmunity and related conditions. Autoimmun Rev 2003; 2: 36-42.
10. Czaja AJ,. Review article: prevention and reversal of hepatic fibrosis in autoimmune hepatitis. Aliment Pharmacol Ther 2014; 39: 385-406.
11. Czaja AJ,. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol 2014; 20: 2515-32.
12. Czaja AJ, Manns MP,. Advances in the diagnosis, pathogenesis and management of autoimmune hepatitis. Gastroenterology 2010; 139: 58-72.
13. Medina J, Garcia-Buey L, Moreno-Otero R,. Review article: immunopathogenetic and therapeutic aspects of autoimmune hepatitis. Aliment Pharmacol Ther 2003; 17: 1-16.
14. Bacon K, Baggiolini M, Broxmeyer H, et al,. Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res 2002; 22: 1067-8.
15. Fernandez EJ, Lolis E,. Structure, function, and inhibition of chemokines. Ann Rev Pharmacol Toxicol 2002; 42: 469-99.
16. Campbell DJ, Kim CH, Butcher EC,. Chemokines in the systemic organization of immunity. Immunol Rev 2003; 195: 58-71.
17. Rot A, von Andrian UH,. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 2004; 22: 891-928.
18. Allen SJ, Crown SE, Handel TM,. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 2007; 25: 787-820.
19. Bonecchi R, Galliera E, Borroni EM, et al,. Chemokines and chemokine receptors: an overview. Front Biosci (Landmark Ed) 2009; 14: 540-51.
20. Sahin H, Trautwein C, Wasmuth HE,. Functional role of chemokines in liver disease models. Nat Rev Gastroenterol Hepatol 2010; 7: 682-90.
21. Sahin H, Wasmuth HE,. Chemokines in tissue fibrosis. Biochim Biophys Acta 2013; 1832: 1041-8.
22. Antonelli A, Ferrari SM, Giuggioli D, et al,. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev 2014; 13: 272-80.
23. Luster AD,. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436-45.
24. Wasmuth HE, Tacke F, Trautwein C,. Chemokines in liver inflammation and fibrosis. Semin Liver Dis 2010; 30: 215-25.
25. Lee EY, Lee ZH, Song YW,. CXCL10 and autoimmune diseases. Autoimmun Rev 2009; 8: 379-83.
26. Colvin RA, Campanella GS, Sun J, et al,. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J Biol Chem 2004; 279: 30219-27.
27. Li YL, Liu N, Zhao DT, et al,. Investigate circulating levels of chemokines and evaluate the correlation between these chemokines and liver function indicators in autoimmune hepatitis. Zhonghua Gan Zang Bing Za Zhi 2013; 21: 299-303.
28. Landi A, Weismuller TJ, Lankisch TO, et al,. Differential serum levels of eosinophilic eotaxins in primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis. J Interferon Cytokine Res 2014; 34: 204-14.
29. Trivedi PJ, Adams DH,. Mucosal immunity in liver autoimmunity: a comprehensive review. J Autoimmun 2013; 46: 97-111.
30. Wehr A, Baeck C, Heymann F, et al,. Chemokine receptor CXCR6-dependent hepatic NK T Cell accumulation promotes inflammation and liver fibrosis. J Immunol 2013; 190: 5226-36.
31. Lei Y, Takahama Y,. XCL1 and XCR1 in the immune system. Microbes Infect 2012; 14: 262-7.
32. Rollins BJ,. Chemokines. Blood 1997; 90: 909-28.
33. Rossi D, Zlotnik A,. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18: 217-42.
34. Czaja AJ,. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol 2001; 96: 1224-31.
35. Czaja AJ,. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev Gastroenterol Hepatol 2007; 1: 113-28.
36. Vergani D, Mieli-Vergani G,. Aetiopathogenesis of autoimmune hepatitis. World J Gastroenterol 2008; 14: 3306-12.
37. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6: 1123-32.
38. Bettelli E, Carrier Y, Gao W, et al,. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-8.
39. Dardalhon V, Korn T, Kuchroo VK, et al,. Role of Th1 and Th17 cells in organ-specific autoimmunity. J Autoimmun 2008; 31: 252-6.
40. Bettelli E, Korn T, Oukka M, et al,. Induction and effector functions of T(H)17 cells. Nature 2008; 453: 1051-7.
41. Korn T, Bettelli E, Oukka M, et al,. IL-17 and Th17 cells. Annu Rev Immunol 2009; 27: 485-517.
42. Yu H, Huang J, Liu Y, et al,. IL-17 contributes to autoimmune hepatitis. J Huazhong Univ Sci Technolog Med Sci 2010; 30: 443-6.
43. Zhao L, Tang Y, You Z, et al,. Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS ONE 2011; 6: e18909.
44. Oo YH, Banz V, Kavanagh D, et al,. CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver. J Hepatol 2012; 57: 1044-51.
45. + regulatory T cells. Nat Immunol 2003; 4: 330-6.
46. Hori S, Nomura T, Sakaguchi S,. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-61.
47. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6: 345-52.
48. Godfrey DI, Hammond KJ, Poulton LD, et al,. NKT cells: facts, functions and fallacies. Immunol Today 2000; 21: 573-83.
49. Dennert G, Aswad F,. The role of NKT cells in animal models of autoimmune hepatitis. Crit Rev Immunol 2006; 26: 453-73.
50. Novak J, Lehuen A,. Mechanism of regulation of autoimmunity by iNKT cells. Cytokine 2011; 53: 263-70.
51. Santodomingo-Garzon T, Swain MG,. Role of NKT cells in autoimmune liver disease. Autoimmun Rev 2011; 10: 793-800.
52. Jeong WI, Park O, Suh YG, et al,. Suppression of innate immunity (natural killer cell/interferon-gamma) in the advanced stages of liver fibrosis in mice. Hepatology 2011; 53: 1342-51.
53. de Lalla C, Galli G, Aldrighetti L, et al,. Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J Immunol 2004; 173: 1417-25.
54. Jin Z, Sun R, Wei H, et al,. Accelerated liver fibrosis in hepatitis B virus transgenic mice: involvement of natural killer T cells. Hepatology 2011; 53: 219-29.
55. Bertolino P,. Interleukin-22, interleukin-17, and other cytokines: a wall is coming down. Hepatology 2008; 47: 345-8.
56. Lemmers A, Moreno C, Gustot T, et al,. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 2009; 49: 646-57.
57. Lan RY, Salunga TL, Tsuneyama K, et al,. Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J Autoimmun 2009; 32: 43-51.
58. Zhang JY, Zhang Z, Lin F, et al,. Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 2010; 51: 81-91.
59. Oo YH, Adams DH,. The role of chemokines in the recruitment of lymphocytes to the liver. J Autoimmun 2010; 34: 45-54.
60. Lee AY, Eri R, Lyons AB, et al,. CC chemokine ligand 20 and its cognate receptor CCR6 in mucosal T cell immunology and inflammatory bowel disease: odd couple or axis of evil? Front Immunol 2013; 4: 194.
61. Huang H, Xu X, Yao C, et al,. Serum levels of CXCR3 ligands predict T cell-mediated acute rejection after kidney transplantation. Mol Med Rep 2014; 9: 45-50.
62. Lohr H, Manns M, Kyriatsoulis A, et al,. Clonal analysis of liver-infiltrating T cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis. Clin Exp Immunol 1991; 84: 297-302.
63. Lohr H, Treichel U, Poralla T, et al,. Liver-infiltrating T helper cells in autoimmune chronic active hepatitis stimulate the production of autoantibodies against the human asialoglycoprotein receptor in vitro. Clin Exp Immunol 1992; 88: 45-9.
64. Czaja AJ,. Autoimmune hepatitis. Evolving concepts and treatment strategies. Dig Dis Sci 1995; 40: 435-56.
65. Bonecchi R, Bianchi G, Bordignon PP, et al,. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998; 187: 129-34.
66. Loetscher P, Uguccioni M, Bordoli L, et al,. CCR5 is characteristic of Th1 lymphocytes. Nature 1998; 391: 344-5.
67. Kim CH, Rott L, Kunkel EJ, et al,. Rules of chemokine receptor association with T cell polarization in vivo. J Clin Invest 2001; 108: 1331-9.
68. Zeremski M, Petrovic LM, Chiriboga L, et al,. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 2008; 48: 1440-50.
69. Farber JM,. Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 1997; 61: 246-57.
70. Sauty A, Dziejman M, Taha RA, et al,. The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. J Immunol 1999; 162: 3549-58.
71. Del Prete G, De Carli M, Almerigogna F, et al,. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 1993; 150: 353-60.
72. Whitacre CC, Reingold SC, O'Looney PA,. A gender gap in autoimmunity Science 1999; 283: 1277-8.
73. Czaja AJ,. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. Semin Liver Dis 2009; 29: 315-30.
74. Heneghan MA, Norris SM, O'Grady JG, et al,. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001; 48: 97-102.
75. Buchel E, Van Steenbergen W, Nevens F, et al,. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol 2002; 97: 3160-5.
76. Schramm C, Herkel J, Beuers U, et al,. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 2006; 101: 556-60.
77. Imai T, Nagira M, Takagi S, et al,. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol 1999; 11: 81-8.
78. Sallusto F, Mackay CR, Lanzavecchia A,. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 1997; 277: 2005-7.
79. Sallusto F, Lanzavecchia A, Mackay CR,. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 1998; 19: 568-74.
80. Zingoni A, Soto H, Hedrick JA, et al,. The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J Immunol 1998; 161: 547-51.
81. Andrew DP, Chang MS, McNinch J, et al,. STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13. J Immunol 1998; 161: 5027-38.
82. da Rocha LF Jr, Dantas AT, Duarte AL, et al,. PPARgamma agonists in adaptive immunity: what do immune disorders and their models have to tell us? PPAR Res 2013; 2013: 519724.
83. Hontecillas R, Bassaganya-Riera J,. Peroxisome proliferator-activated receptor gamma is required for regulatory CD4+ T cell-mediated protection against colitis. J Immunol 2007; 178: 2940-9.
84. Saeki C, Nakano M, Takahashi H, et al,. Accumulation of functional regulatory T cells in actively inflamed liver in mouse dendritic cell-based autoimmune hepatic inflammation. Clin Immunol 2010; 135: 156-66.
85. + T lymphocytes with regulatory activity. J Immunol 2001; 166: 996-1002.
86. + regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol 2009; 183: 7602-10.
87. Wang J, Ioan-Facsinay A, van der Voort EI, et al,. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007; 37: 129-38.
88. Liu W, Putnam AL, Xu-Yu Z, et al,. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 203: 1701-11.
89. Borsellino G, Kleinewietfeld M, Di Mitri D, et al,. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007; 110: 1225-32.
90. Wieczorek G, Asemissen A, Model F, et al,. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res 2009; 69: 599-608.
91. Peiseler M, Sebode M, Franke B, et al,. FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. J Hepatol 2012; 57: 125-32.
92. Zheng SG, Wang J, Wang P, et al,. IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol 2007; 178: 2018-27.
93. Chen W, Jin W, Hardegen N, et al,. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198: 1875-86.
94. Huber S, Schramm C, Lehr HA, et al,. Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J Immunol 2004; 173: 6526-31.
95. Rao PE, Petrone AL, Ponath PD,. Differentiation and expansion of T cells with regulatory function from human peripheral lymphocytes by stimulation in the presence of TGF-{beta}. J Immunol 2005; 174: 1446-55.
96. de la Rosa M, Rutz S, Dorninger H, et al,. Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur J Immunol 2004; 34: 2480-8.
97. Brandenburg S, Takahashi T, de la Rosa M, et al,. IL-2 induces in vivo suppression by CD4(+)CD25(+)Foxp3(+) regulatory T cells. Eur J Immunol 2008; 38: 1643-53.
98. Muller M, Carter SL, Hofer MJ, et al,. CXCR3 signaling reduces the severity of experimental autoimmune encephalomyelitis by controlling the parenchymal distribution of effector and regulatory T cells in the central nervous system. J Immunol 2007; 179: 2774-86.
99. Wei S, Kryczek I, Zou W,. Regulatory T-cell compartmentalization and trafficking. Blood 2006; 108: 426-31.
100. Sakaki M, Hiroishi K, Baba T, et al,. Intrahepatic status of regulatory T cells in autoimmune liver diseases and chronic viral hepatitis. Hepatol Res 2008; 38: 354-61.
101. Longhi MS, Ma Y, Bogdanos DP, et al,. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol 2004; 41: 31-7.
102. Grant CR, Liberal R, Holder BS, et al,. Dysfunctional CD39(POS) regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis. Hepatology 2014; 59: 1007-15.
103. Wu L, Van Kaer L,. Natural killer T cells in health and disease. Front Biosci (Schol Ed) 2011; 3: 236-51.
104. Czaja AJ,. Nonstandard drugs and feasible new interventions for autoimmune hepatitis. Part-II. Inflamm Allergy Drug Targets 2012; 11: 351-63.
105. Zeissig S, Blumberg RS,. Primary immunodeficiency associated with defects in CD1 and CD1-restricted T cells. Ann N Y Acad Sci 2012; 1250: 14-24.
106. Nowak M, Stein-Streilein J,. Invariant NKT cells and tolerance. Int Rev Immunol 2007; 26: 95-119.
107. Geissmann F, Cameron TO, Sidobre S, et al,. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol 2005; 3: e113.
108. Omenetti A, Syn WK, Jung Y, et al,. Repair-related activation of hedgehog signaling promotes cholangiocyte chemokine production. Hepatology 2009; 50: 518-27.
109. Abel S, Hundhausen C, Mentlein R, et al,. The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol 2004; 172: 6362-72.
110. Shimaoka T, Nakayama T, Fukumoto N, et al,. Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells. J Leukoc Biol 2004; 75: 267-74.
111. Heydtmann M, Lalor PF, Eksteen JA, et al,. CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver. J Immunol 2005; 174: 1055-62.
112. Baecher-Allan C, Viglietta V, Hafler DA,. Inhibition of human CD4(+)CD25(+high) regulatory T cell function. J Immunol 2002; 169: 6210-7.
113. Hennes EM, Zeniya M, Czaja AJ, et al,. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-76.
114. Czaja AJ,. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology 2008; 48: 1540-8.
115. Manousou P, Kolios G, Drygiannakis I, et al,. CXCR3 axis in patients with primary biliary cirrhosis: a possible novel mechanism of the effect of ursodeoxycholic acid. Clin Exp Immunol 2013; 172: 9-15.
116. Padovan E, Spagnoli GC, Ferrantini M, et al,. IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. J Leukoc Biol 2002; 71: 669-76.
117. Antonelli A, Fallahi P, Ferrari SM, et al,. High circulating chemokines (C-X-C motif) ligand 9, and (C-X-C motif) ligand 11, in hepatitis C-associated cryoglobulinemia. Int J Immunopathol Pharmacol 2013; 26: 49-57.
118. Garcia-Lopez MA, Sanchez-Madrid F, Rodriguez-Frade JM, et al,. CXCR3 chemokine receptor distribution in normal and inflamed tissues: expression on activated lymphocytes, endothelial cells, and dendritic cells. Lab Invest 2001; 81: 409-18.
119. Narumi S, Takeuchi T, Kobayashi Y, et al,. Serum levels of ifn-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus. Cytokine 2000; 12: 1561-5.
120. Nishioji K, Okanoue T, Itoh Y, et al,. Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes. Clin Exp Immunol 2001; 123: 271-9.
121. Antonelli A, Ferri C, Fallahi P, et al,. High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis. Cytokine 2008; 42: 137-43.
122. Antonelli A, Fallahi P, Ferrari SM, et al,. Circulating CXCL11 and CXCL10 are increased in hepatitis C-associated cryoglobulinemia in the presence of autoimmune thyroiditis. Mod Rheumatol 2012; 22: 659-67.
123. Zeremski M, Dimova R, Astemborski J, et al,. CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C. J Infect Dis 2011; 204: 832-6.
124. Brownell J, Polyak SJ,. Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer. Clin Cancer Res 2013; 19: 1347-52.
125. Cole KE, Strick CA, Paradis TJ, et al,. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998; 187: 2009-21.
126. Baba M, Imai T, Nishimura M, et al,. Identification of CCR6, the specific receptor for a novel lymphocyte-directed CC chemokine LARC. J Biol Chem 1997; 272: 14893-8.
127. Hieshima K, Imai T, Opdenakker G, et al,. Molecular cloning of a novel human CC chemokine liver and activation-regulated chemokine (LARC) expressed in liver. Chemotactic activity for lymphocytes and gene localization on chromosome 2. J Biol Chem 1997; 272: 5846-53.
128. Iwamoto S, Kido M, Aoki N, et al,. TNF-alpha is essential in the induction of fatal autoimmune hepatitis in mice through upregulation of hepatic CCL20 expression. Clin Immunol 2013; 146: 15-25.
129. Affo S, Morales-Ibanez O, Rodrigo-Torres D, et al,. CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis. Gut 2014; doi: 10.1136/gutjnl-2013-306098 [Epub ahead of print].
130. Schutyser E, Struyf S, Van Damme J,. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev 2003; 14: 409-26.
131. Shimizu Y, Murata H, Kashii Y, et al,. CC-chemokine receptor 6 and its ligand macrophage inflammatory protein 3alpha might be involved in the amplification of local necroinflammatory response in the liver. Hepatology 2001; 34: 311-9.
132. Yamauchi K, Akbar SM, Horiike N, et al,. Increased serum levels of macrophage inflammatory protein-3alpha in chronic viral hepatitis: prognostic importance of macrophage inflammatory protein-3alpha during interferon therapy in chronic hepatitis C. J Viral Hepat 2002; 9: 213-20.
133. Coulomb-L'Hermin A, Amara A, Schiff C, et al,. Stromal cell-derived factor 1 (SDF-1) and antenatal human B cell lymphopoiesis: expression of SDF-1 by mesothelial cells and biliary ductal plate epithelial cells. Proc Natl Acad Sci U S A 1999; 96: 8585-90.
134. Terada R, Yamamoto K, Hakoda T, et al,. Stromal cell-derived factor-1 from biliary epithelial cells recruits CXCR4-positive cells: implications for inflammatory liver diseases. Lab Invest 2003; 83: 665-72.
135. Dotan I, Werner L, Vigodman S, et al,. CXCL12 is a constitutive and inflammatory chemokine in the intestinal immune system. Inflamm Bowel Dis 2010; 16: 583-92.
136. Tsuchiya A, Imai M, Kamimura H, et al,. Increased susceptibility to severe chronic liver damage in CXCR4 conditional knock-out mice. Dig Dis Sci 2012; 57: 2892-900.
137. Hong F, Tuyama A, Lee TF, et al,. Hepatic stellate cells express functional CXCR4: role in stromal cell-derived factor-1alpha-mediated stellate cell activation. Hepatology 2009; 49: 2055-67.
138. Saiman Y, Agarwal R, Hickman DA, et al,. CXCL12 induces hepatic stellate cell contraction through a calcium-independent pathway. Am J Physiol Gastrointest Liver Physiol 2013; 305: G375-82.
139. Mohle R, Bautz F, Rafii S, et al,. The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood 1998; 91: 4523-30.
140. Ma Q, Jones D, Springer TA,. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 1999; 10: 463-71.
141. Berahovich RD, Zabel BA, Lewen S, et al,. Endothelial expression of CXCR7 and the regulation of systemic CXCL12 levels. Immunology 2014; 141: 111-22.
142. Schimanski CC, Bahre R, Gockel I, et al,. Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4. Br J Cancer 2006; 95: 210-7.
143. Sutton A, Friand V, Brule-Donneger S, et al,. Stromal cell-derived factor-1/chemokine (C-X-C motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion. Mol Cancer Res 2007; 5: 21-33.
144. Sakai N, Yoshidome H, Shida T, et al,. CXCR4/CXCL12 expression profile is associated with tumor microenvironment and clinical outcome of liver metastases of colorectal cancer. Clin Exp Metastasis 2012; 29: 101-10.
145. Puchert M, Engele J,. The peculiarities of the SDF-1/CXCL12 system: in some cells, CXCR4 and CXCR7 sing solos, in others, they sing duets. Cell Tissue Res 2014; 355: 239-53.
146. Wald O, Pappo O, Safadi R, et al,. Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus. Eur J Immunol 2004; 34: 1164-74.
147. Cho HK, Kim SY, Seong JK, et al,. Hepatitis B virus X increases immune cell recruitment by induction of chemokine SDF-1. FEBS Lett 2014; 588: 733-9.
148. Tanegashima K, Suzuki K, Nakayama Y, et al,. CXCL14 is a natural inhibitor of the CXCL12-CXCR4 signaling axis. FEBS Lett 2013; 587: 1731-5.
149. Costantini S, Raucci R, Colonna G, et al,. Peptides targeting chemokine receptor CXCR4: structural behavior and biological binding studies. J Pept Sci 2014; 20: 270-8.
150. Blanchetot C, Verzijl D, Mujic-Delic A, et al,. Neutralizing nanobodies targeting diverse chemokines effectively inhibit chemokine function. J Biol Chem 2013; 288: 25173-82.
151. Bourd-Boittin K, Basset L, Bonnier D, et al,. CX3CL1/fractalkine shedding by human hepatic stellate cells: contribution to chronic inflammation in the liver. J Cell Mol Med 2009; 13: 1526-35.
152. Shimoda S, Harada K, Niiro H, et al,. CX3CL1 (fractalkine): a signpost for biliary inflammation in primary biliary cirrhosis. Hepatology 2010; 51: 567-75.
153. White GE, Greaves DR,. Fractalkine: a survivor's guide: chemokines as antiapoptotic mediators. Arterioscler Thromb Vasc Biol 2012; 32: 589-94.
154. Aspinall AI, Curbishley SM, Lalor PF, et al,. CX(3)CR1 and vascular adhesion protein-1-dependent recruitment of CD16(+) monocytes across human liver sinusoidal endothelium. Hepatology 2010; 51: 2030-9.
155. Karlmark KR, Zimmermann HW, Roderburg C, et al,. The fractalkine receptor CX(3)CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. Hepatology 2010; 52: 1769-82.
156. Aoyama T, Inokuchi S, Brenner DA, et al,. CX3CL1-CX3CR1 interaction prevents carbon tetrachloride-induced liver inflammation and fibrosis in mice. Hepatology 2010; 52: 1390-400.
157. Imai T, Hieshima K, Haskell C, et al,. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997; 91: 521-30.
158. Lucas AD, Bursill C, Guzik TJ, et al,. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation 2003; 108: 2498-504.
159. Isse K, Harada K, Zen Y, et al,. Fractalkine and CX3CR1 are involved in the recruitment of intraepithelial lymphocytes of intrahepatic bile ducts. Hepatology 2005; 41: 506-16.
160. Okamura A, Harada K, Nio M, et al,. Participation of natural killer cells in the pathogenesis of bile duct lesions in biliary atresia. J Clin Pathol 2013; 66: 99-108.
161. Garcia-Alvarez M, Berenguer J, Guzman-Fulgencio M, et al,. High plasma fractalkine (CX3CL1) levels are associated with severe liver disease in HIV/HCV co-infected patients with HCV genotype 1. Cytokine 2011; 54: 244-8.
162. Wasmuth HE, Zaldivar MM, Berres ML, et al,. The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. J Hepatol 2008; 48: 208-15.
163. Efsen E, Grappone C, DeFranco RM, et al,. Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. J Hepatol 2002; 37: 39-47.
164. Borchers AT, Shimoda S, Bowlus C, et al,. Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis. Semin Immunopathol 2009; 31: 309-22.
165. Sasaki M, Miyakoshi M, Sato Y, et al,. Modulation of the microenvironment by senescent biliary epithelial cells may be involved in the pathogenesis of primary biliary cirrhosis. J Hepatol 2010; 53: 318-25.
166. Sasaki M, Miyakoshi M, Sato Y, et al,. Chemokine-chemokine receptor CCL2-CCR2 and CX3CL1-CX3CR1 axis may play a role in the aggravated inflammation in primary biliary cirrhosis. Dig Dis Sci 2014; 59: 358-64.
167. Zhang W, Ono Y, Miyamura Y, et al,. T cell clonal expansions detected in patients with primary biliary cirrhosis express CX3CR1. J Autoimmun 2011; 37: 71-8.
168. Harada K, Kakuda Y, Nakamura M, et al,. Clinicopathological significance of serum fractalkine in primary biliary cirrhosis. Dig Dis Sci 2013; 58: 3037-43.
169. Shinkai A, Yoshisue H, Koike M, et al,. A novel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity toward eosinophils. J Immunol 1999; 163: 1602-10.
170. Kitaura M, Suzuki N, Imai T, et al,. Molecular cloning of a novel human CC chemokine (Eotaxin-3) that is a functional ligand of CC chemokine receptor 3. J Biol Chem 1999; 274: 27975-80.
171. Strieter RM, Burdick MD, Gomperts BN, et al,. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 593-609.
172. Fernandez M, Semela D, Bruix J, et al,. Angiogenesis in liver disease. J Hepatol 2009; 50: 604-20.
173. Wynn TA,. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004; 4: 583-94.
174. Holt AP, Haughton EL, Lalor PF, et al,. Liver myofibroblasts regulate infiltration and positioning of lymphocytes in human liver. Gastroenterology 2009; 136: 705-14.
175. Keeley EC, Mehrad B, Strieter RM,. Chemokines as mediators of neovascularization. Arterioscler Thromb Vasc Biol 2008; 28: 1928-36.
176. Marra F, DeFranco R, Grappone C, et al,. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol 1998; 152: 423-30.
177. Caligiuri A, Bertolani C, Guerra CT, et al,. Adenosine monophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells. Hepatology 2008; 47: 668-76.
178. Seki E, de Minicis S, Inokuchi S, et al,. CCR2 promotes hepatic fibrosis in mice. Hepatology 2009; 50: 185-97.
179. Seki E, De Minicis S, Gwak GY, et al,. CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest 2009; 119: 1858-70.
180. Berres ML, Koenen RR, Rueland A, et al,. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest 2010; 120: 4129-40.
181. Syrbe U, Siveke J, Hamann A,. Th1/Th2 subsets: distinct differences in homing and chemokine receptor expression? Springer Semin Immunopathol 1999; 21: 263-85.
182. Hintermann E, Bayer M, Pfeilschifter JM, et al,. CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation. J Autoimmun 2010; 35: 424-35.
183. Zaldivar MM, Pauels K, von Hundelshausen P, et al,. CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology 2010; 51: 1345-53.
184. Yeoman AD, Longhi MS, Heneghan MA,. Review article: the modern management of autoimmune hepatitis. Aliment Pharmacol Ther 2010; 31: 771-87.
185. Zachou K, Muratori P, Koukoulis GK, et al,. Review article: autoimmune hepatitis-current management and challenges. Aliment Pharmacol Ther 2013; 38: 887-913.
186. Czaja AJ,. Review article: permanent drug withdrawal is desirable and achievable for autoimmune hepatitis. Aliment Pharmacol Ther 2014; 39: 1043-58.
187. Baven-Pronk AM, Coenraad MJ, van Buuren HR, et al,. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther 2011; 34: 335-43.
188. Selvarajah V, Montano-Loza AJ, Czaja AJ,. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther 2012; 36: 691-707.
189. Czaja AJ,. Review article: the management of autoimmune hepatitis beyond consensus guidelines. Aliment Pharmacol Ther 2013; 38: 343-64.
190. Czaja AJ,. Drug choices in autoimmune hepatitis: Part B-nonsteroids. Expert Rev Gastroenterol Hepatol 2012; 6: 617-35.
191. Shibutani S, Inoue F, Aramaki O, et al,. Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen. Transplantation 2005; 79: 904-13.
192. Lim DG, Joe IY, Park YH, et al,. Effect of immunosuppressants on the expansion and function of naturally occurring regulatory T cells. Transpl Immunol 2007; 18: 94-100.
193. Demirkiran A, Sewgobind VD, van der Weijde J, et al,. Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4+FOXP3+ regulatory T cells. Transplantation 2009; 87: 1062-8.
194. Miroux C, Morales O, Ouaguia L, et al,. Corticosteroids do not reverse the inhibitory effect of cyclosporine on regulatory T-cell activity in contrast to mycophenolate mofetil. Transplant Proc 2012; 44: 2834-9.
195. Wei HX, Chuang YH, Li B, et al,. CD4+ CD25+ Foxp3+ regulatory T cells protect against T cell-mediated fulminant hepatitis in a TGF-beta-dependent manner in mice. J Immunol 2008; 181: 7221-9.
196. Longhi MS, Hussain MJ, Kwok WW, et al,. Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis. Hepatology 2011; 53: 536-47.
197. Longhi MS, Ma Y, Mieli-Vergani G, et al,. Regulatory T cells in autoimmune hepatitis. J Hepatol 2012; 57: 932-3.
198. Longhi MS, Meda F, Wang P, et al,. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology 2008; 47: 581-91.
199. Lapierre P, Beland K, Yang R, et al,. Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance. Hepatology 2013; 57: 217-27.
200. Czaja AJ,. Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis. Dig Dis Sci 2010; 55: 2712-26.
201. Burak KW, Swain MG, Santodomino-Garzon T, et al,. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol 2013; 27: 273-80.
202. Weiler-Normann C, Schramm C, Quaas A, et al,. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol 2013; 58: 529-34.
203. Saitis A, Gatselis N, Zachou K, et al,. Use of TNFalpha antagonists in refractory AIH: revealing the unforeseen. J Hepatol 2013; 59: 197-8.
204. Germano V, Picchianti Diamanti A, Baccano G, et al,. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005; 64: 1519-20.
205. Marques M, Magro F, Cardoso H, et al,. Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis. Inflamm Bowel Dis 2008; 14: 723-5.
206. Fairhurst DA, Sheehan-Dare R,. Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriaisis. Clin Exp Dermatol 2009; 34: 421-2.
207. Pascual G, Fong AL, Ogawa S, et al,. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005; 437: 759-63.
208. Antonelli A, Rotondi M, Ferrari SM, et al,. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2006; 91: 614-20.
209. Antonelli A, Ferrari SM, Fallahi P, et al,. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2009; 94: 1803-9.
210. Antonelli A, Ferrari SM, Frascerra S, et al,. Peroxisome proliferator-activated receptor alpha agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves' disease. Exp Cell Res 2011; 317: 1527-33.
211. Lee JW, Bajwa PJ, Carson MJ, et al,. Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10- deficient mice. Gastroenterology 2007; 133: 108-23.
212. Crescioli C, Cosmi L, Borgogni E, et al,. Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. J Endocrinol 2007; 195: 145-55.
213. Yellin M, Paliienko I, Balanescu A, et al,. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2012; 64: 1730-9.
214. Xu HB, Gong YP, Cheng J, et al,. CXCL16 participates in pathogenesis of immunological liver injury by regulating T lymphocyte infiltration in liver tissue. World J Gastroenterol 2005; 11: 4979-85.
215. Harmsen MM, De Haard HJ,. Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol 2007; 77: 13-22.